Driehaus Capital Management 13F: Cuts DFTX Stake by $29M

Driehaus Capital Management has trimmed its position in Definium Therapeutics, Inc. (NasdaqGS: DFTX), cutting 625,313 shares. This represents a 9.57% decrease, bringing its total holdings to 5,911,889 shares valued at approximately $146.3 million, according to its latest Form 13F filing with the SEC, reflecting holdings as of the end of the reporting period.

What Changed in Driehaus Capital Management's Definium Therapeutics Position

Driehaus Capital Management reduced its stake in Definium Therapeutics from 6,537,202 shares to 5,911,889 shares, a decrease of 625,313 shares or 9.57%. The value of the current holdings is about $146.3 million.

Other Institutional Activity in Definium Therapeutics

Several other institutional investors have also adjusted their positions in Definium Therapeutics. BlackRock, Inc. grew its holdings significantly, adding 8,480,230 shares to reach a total of 8,480,230 shares valued at about $160.3 million. Avoro Capital Advisors LLC added 5,000,000 shares, ending with 5,000,000 shares worth approximately $94.5 million. Janus Henderson Group PLC acquired 3,556,041 shares, totaling shares valued at $67.2 million. Deep Track Capital, LP increased its holdings by 3,000,000 shares, reaching 3,000,000 shares valued at $56.7 million.

Definium Therapeutics, Inc. Stock Up 21.2%

Shares of NasdaqGS: DFTX traded near $24.75. Definium Therapeutics has a market cap of approximately $2.7 billion and a forward P/E ratio of -15.66, indicating it is not currently profitable. The stock has a 52-week low of $6.35 and a high of $26.25, with a 50-day moving average of $22.33 and a 200-day moving average of $15.99. The company's beta is 2.378, suggesting higher volatility compared to the market.

Recent Earnings

Definium Therapeutics has not reported positive earnings, with an EPS of -2.5. The company has a return on equity of -94.7% and a net margin of 0.0%. Investors can expect the next earnings report on July 30, 2026.

Insider Buying and Selling at Definium Therapeutics, Inc.

Recent insider transactions include planned sales on March 25, 2026, by Chief Legal Officer Mark Sullivan (10,702 shares), Chief Medical Officer Daniel Karlin (8,018 shares), and CEO Robert Barrow (24,431 shares), all at an average price of $18.47. Earlier, on February 3, 2026, CEO Robert Barrow purchased 320,000 shares, Chief Legal Officer Mark Sullivan bought 125,000 shares, and Chief Commercial Officer Matthew Wiley acquired 115,000 shares at no cost.

Analysts Set New Price Targets

On May 8, 2026, Piper Sandler maintained a buy rating with a $48 price target. Earlier, on April 22, 2026, Leerink Partners maintained a buy rating with a $30 target. Stifel initiated coverage with a buy rating and a $30 target on April 17, 2026. The consensus among 15 analysts is a strong buy, with a mean target price of $39.87.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biotechnology company based in New York, NY, focused on developing treatments for brain health disorders. Its main products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. The company, led by CEO Robert Barrow, employs 105 people and was previously known as Mind Medicine (MindMed) Inc. before its name change in January 2026.

Bottom Line

Driehaus Capital Management's decision to reduce its stake in Definium Therapeutics signals a shift in its investment strategy. Investors continue to monitor Definium, a company with promising product candidates in the biotech sector. The backward-looking 13F filing reflects past holdings and may not indicate current positions.